Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Home-Use Product Emphasis Displaces Long-Term Care, Physicians

This article was originally published in The Gray Sheet

Executive Summary

The Ministry of Health, Labor & Welfare in Japan is displacing fees paid to long-term care (LTC) institutions in favor of the home-care sector, according to a Japanese health economist

You may also be interested in...



Japan’s MHLW Increases User Fee Rates, Earmarks Postmarket Device Staff

The Pharmaceutical & Medical Device Organization in Japan plans to increase its device review staff from 19 employees to 38 by 2009

Japan’s MHLW Increases User Fee Rates, Earmarks Postmarket Device Staff

The Pharmaceutical & Medical Device Organization in Japan plans to increase its device review staff from 19 employees to 38 by 2009

International News In Brief

BD's Edward Ludwig: Becton Dickinson CEO/AdvaMed International Board Committee chair appointed as one of eight U.S. industry reps on U.S.-Japan Private Sector-Government Commission. Launched in 2001 by Prime Minister Koizumi and President Bush, the commission generates economic reform recommendations to enable further cooperation between industry and the two governments. At an April 14 commission meeting, Ludwig discussed the importance of leveraging the role of medical devices as an economic growth engine in Japan, using healthcare technologies to drive productivity, and meeting the demands of the country's aging population. A final report is due in November...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel